Drug company Valeant Pharmaceuticals Inc (VRX.TO) is under pressure from investors to introduce more transparency into its operations and expand its management ranks to regain credibility in the investment community, people familiar with the situation said.
The company is on Friday holding its first board meeting since appointing three new outside directors, the people said. It was not immediately clear whether these specific issues would be on the agenda.
The company is on Friday holding its first board meeting since appointing three new outside directors, the people said. It was not immediately clear whether these specific issues would be on the agenda.
